Business Context and Reporting Period
Company: Gilead Sciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2003
Overview: Gilead is a biopharmaceutical company focused on anti-infectives, specifically antivirals and antifungals. The company markets six products globally, with a primary focus on HIV (Viread, Emtriva) and Hepatitis B (Hepsera). In January 2003, Gilead completed the acquisition of Triangle Pharmaceuticals, Inc. for $525.2 million to expand its antiviral pipeline, resulting in the FDA approval of Emtriva in July 2003.
Key Financial Metrics
| Metric | 2003 | 2002 |
|---|---|---|
| Total Revenues | $867.9 million | $466.8 million |
| Net Income (Loss) | $(72.0) million | $72.1 million |
| Operating Income (Loss) | $(158.7) million | $81.0 million |
| Cash Flow from Operations | $234.6 million | $74.4 million |
| Product Gross Margin | 86.5% | 83.6% |
| Research & Development Expenses | $164.9 million | $134.8 million |
| Cash & Marketable Securities | $707.0 million | $942.4 million |
| Convertible Debt | $345.0 million | $595.0 million |
Note: The 2003 net loss is primarily driven by a non-cash charge of $488.6 million for in-process research and development (IPR&D) related to the Triangle acquisition.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 86% year-over-year, driven by a 151% increase in Viread sales ($566.5 million) and a 7% increase in AmBisome sales. Viread now accounts for 65% of total revenues.
- Profitability Impact: Despite strong operational cash flow and revenue growth, the company reported a net loss of $72.0 million compared to a net income of $72.1 million in 2002. This reversal was caused by the $488.6 million IPR&D charge and a $10.2 million asset impairment charge related to the discontinuation of the DaunoXome product line.
- Tax Benefit: The company recorded a significant income tax benefit of $111.6 million in Q4 2003 due to the reversal of a valuation allowance on deferred tax assets, which improved the bottom line but did not affect cash flow.
- Debt Structure: In December 2003, Gilead converted $250.0 million of 5% convertible subordinated notes into common stock, reducing interest expense for the upcoming year.
Guidance, Outlook, and Risks
- 2004 Revenue Outlook:
- Viread: Expected to grow 25-30%, reaching $700 million to $750 million.
- AmBisome: Expected to decline to $160 million to $180 million due to increasing competition in Europe.
- 2004 Expense Outlook:
- R&D: Projected at $200 million to $220 million (20-30% increase), driven by the development of a fixed-dose combination of Viread and Emtriva.
- SG&A: Projected at $310 million to $330 million (25-30% increase) to support expanded marketing.
- Key Risks:
- Product Concentration: 90% of revenues are derived from Viread and AmBisome.
- Competition: AmBisome faces strong competition from new antifungal agents; Viread faces a crowded HIV market.
- Regulatory & Safety: Potential for new safety warnings (e.g., kidney toxicity with Viread) or failure to obtain approvals for new indications.
- Manufacturing: Reliance on third-party manufacturers for antiviral products and single-source suppliers for key raw materials.
- Legal: Pending litigation regarding Average Wholesale Price (AWP) reporting and a securities class action lawsuit.
Investor Verification Checklist
- Triangle Acquisition Integration: Verify the commercial performance of Emtriva and the timeline for the Viread/Emtriva fixed-dose combination approval.
- AmBisome Volume Trends: Confirm the extent of volume erosion in Europe due to competition from Caspofungin and Voriconazole.
- Deferred Tax Assets: Assess the sustainability of the $111.6 million tax benefit and the remaining $59.2 million valuation allowance.
- European Receivables: Review the aging of accounts receivable in Greece, Spain, Portugal, and Italy, where $102.7 million was past due as of year-end.
- Legal Exposure: Monitor the status of the Westchester County AWP lawsuit and the securities class action regarding alleged misleading statements.